IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...

The company is currently evaluating internal options as well as potential strategic alternatives with the goal of maximizing value for its shareholders. The company also announced that it is reducing ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies MOUNTAIN VIEW, Calif., Nov. 04 ...

Sustainalytics’ controversies research identifies companies involved in incidents and events that may negatively affect stakeholders, the environment or the company’s operations. Controversies are ...

After hours: 7:37:51 p.m. EST ...